Cytogenetics and molecular cytogenetics in diffuse large B-cell lymphoma (DLBCL)

被引：15

作者：

Nedomova, Radka ^{[1
]}

Papajik, Tomas ^{[1
]}

Prochazka, Vit ^{[1
]}

Indrak, Karel ^{[1
]}

Jarosova, Marie ^{[1
]}

机构：

[1] Palacky Univ Olomouc, Fac Med & Dent, Dept Hematooncol, Olomouc, Czech Republic

来源：

BIOMEDICAL PAPERS-OLOMOUC | 2013年 / 157卷 / 03期

关键词：

diffuse large B-cell lymphoma; prognostic subgroups; chromosomal aberrations; molecular cytogenetics; arrayCGH; COMPARATIVE GENOMIC HYBRIDIZATION; IN-SITU HYBRIDIZATION; BCL6; REARRANGEMENT; DISTINCT SUBGROUPS; POOR-PROGNOSIS; EXPRESSION; AMPLIFICATION; PATHOGENESIS; MYC; PROFILES;

D O I：

10.5507/bp.2012.085

中图分类号：

R318 [生物医学工程];

学科分类号：

0831 ;

摘要：

Background. Diffuse large B-cell lymphoma (DLBCL) accounts for up to 40% of all non-Hodgkin's lymphomas diagnosed in the western hemisphere. Determination of the gene expression profile has confirmed the physiological heterogeneity of the disease and defined three molecular prognostic subgroups - germinal center B-cell-like (GCB), activated B-cell-like (ABC) and primary mediastinal B-cell lymphoma (PMBL) - with different gene expression and prognosis. Methods and Results. This review covers current knowledge on the most frequent recurrent cytogenetic and molecular cytogenetic aberrations in molecular DLBCL subgroups. Conclusions. Cytogenetic and molecular cytogenetic techniques used to determine nonrandom chromosomal aberrations in patients with DLBCL have revealed the incidence of frequent cytogenetic aberrations in the subgroups reported, suggesting their potential use for more accurate prognostic stratification of DLBCL, contributing to personalized selection of the most effective therapy.

引用

页码：239 / 247

页数：9

共 40 条

[1]

Akasaka H, 2000, CANCER RES, V60, P2335

[2] Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling [J].

Alizadeh, AA ;

Eisen, MB ;

Davis, RE ;

Ma, C ;

Lossos, IS ;

Rosenwald, A ;

Boldrick, JG ;

Sabet, H ;

Tran, T ;

Yu, X ;

Powell, JI ;

Yang, LM ;

Marti, GE ;

Moore, T ;

Hudson, J ;

Lu, LS ;

Lewis, DB ;

Tibshirani, R ;

Sherlock, G ;

Chan, WC ;

Greiner, TC ;

Weisenburger, DD ;

Armitage, JO ;

Warnke, R ;

Levy, R ;

Wilson, W ;

Grever, MR ;

Byrd, JC ;

Botstein, D ;

Brown, PO ;

Staudt, LM .

NATURE, 2000, 403 (6769) :503-511

[3] Double-hit B-cell lymphomas [J].

Aukema, Sietse M. ;

Siebert, Reiner ;

Schuuring, Ed ;

van Imhoff, Gustaaf W. ;

Kluin-Nelemans, Hanneke C. ;

Boerma, Evert-Jan ;

Kluin, Philip M. .

BLOOD, 2011, 117 (08) :2319-2331

[4] Rearrangement of MYC Is Associated With Poor Prognosis in Patients With Diffuse Large B-Cell Lymphoma Treated in the Era of Rituximab [J].

Barrans, Sharon ;

Crouch, Simon ;

Smith, Alex ;

Turner, Kathryn ;

Owen, Roger ;

Patmore, Russell ;

Roman, Eve ;

Jack, Andrew .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (20) :3360-3365

[5]

Barrans SL, 2003, CLIN CANCER RES, V9, P2133

[6] Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction [J].

Bea, S ;

Zettl, A ;

Wright, G ;

Salaverria, I ;

Jehn, P ;

Moreno, V ;

Burek, C ;

Ott, G ;

Puig, X ;

Yang, LM ;

Lopez-Guillermo, A ;

Chan, WC ;

Greiner, TC ;

Weisenburger, DD ;

Armitage, JO ;

Gascoyne, RD ;

Connors, JM ;

Grogan, TM ;

Braziel, R ;

Fisher, RI ;

Smeland, EB ;

Kvaloy, S ;

Holte, H ;

Delabie, J ;

Simon, R ;

Powell, J ;

Wilson, WH ;

Jaffe, ES ;

Montserrat, E ;

Muller-Hermelink, HK ;

Staudt, LM ;

Campo, E ;

Rosenwald, A .

BLOOD, 2005, 106 (09) :3183-3190

[7] CNS involvement in primary mediastinal large B-cell lymphoma [J].

Bishop, PC ;

Wilson, WH ;

Pearson, D ;

Janik, J ;

Jaffe, ES ;

Elwood, PC .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (08) :2479-2485

[8] BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor [J].

Chang, CC ;

Ye, BH ;

Chaganti, RSK ;

DallaFavera, R .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (14) :6947-6952

[9] Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma [J].

Dunleavy, Kieron ;

Pittaluga, Stefania ;

Czuczman, Myron S. ;

Dave, Sandeep S. ;

Wright, George ;

Grant, Nicole ;

Shovlin, Margaret ;

Jaffe, Elaine S. ;

Janik, John E. ;

Staudt, Louis M. ;

Wilson, Wyndham H. .

BLOOD, 2009, 113 (24) :6069-6076

[10] Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma [J].

Green, Michael R. ;

Monti, Stefano ;

Rodig, Scott J. ;

Juszczynski, Przemyslaw ;

Currie, Treeve ;

O'Donnell, Evan ;

Chapuy, Bjoern ;

Takeyama, Kunihiko ;

Neuberg, Donna ;

Golub, Todd R. ;

Kutok, Jeffery L. ;

Shipp, Margaret A. .

BLOOD, 2010, 116 (17) :3268-3277

← 1 2 3 4 →